Patient-Focused Clinical Trial Design for Rare Diseases – Part 1
A few months ago, Medpace and the Cincinnati Children’s Hospital Medical Center presented a webinar on the importance of patient-centric clinical research. Over the next…
Q&A with Dr. Richard Scheyer: Novel Approaches to Confirming CNS Penetration and Target Engagement
Richard Scheyer, MD, Vice President, Medical Affairs at Medpace answers some questions about his upcoming presentation about CNS-targeted therapies at DIA 2018.
How Rare Diseases Are Showing the Way Toward Precision Medicine – Part 3
In our previous post, we discussed the approaches to help you identify, enroll and retain rare disease populations in clinical trials. Once the right patients…
How to Identify, Enroll, and Retain Rare Disease Populations in Clinical Trials
Enrolling enough subjects into a rare disease study can seem like an insurmountable challenge, especially when you're looking at a subset of a rare disease,…
How Rare Diseases Are Showing the Way Toward Precision Medicine – Part 1
In Part 1 of a 3 part blog series, we will explore how the heritability of neurological diseases and psychiatric diseases is changing the clinical…
Duchenne Muscular Dystrophy: Challenges in Clinical Research
Duchenne Muscular Dystrophy (DMD) is a specific type of muscular dystrophy characterized by muscle weakness and deterioration. DMD research comes with its fair share of…
Biomarkers for Celiac Disease Clinical Trials
As a full service, global CRO with an integrated central lab, Medpace has the scientific, operational and regulatory expertise to manage your celiac disease clinical…
How important is patient-centricity in rare disease studies?
Patient-centricity is becoming increasingly important in all areas, but particularly in rare diseases. In this post, Dr. Richard Scheyer discusses the importance of patient-centricity in…
How to Leverage Research Networks to Accelerate Orphan Drug Development
In this post, Dr. Terence Eagleton highlights the growing interest in the development of products in the rare disease space, the unique challenges involved, and…